Aktienanalyse zu Medtronic PLC (MDT)MDTMedtronic PLC

Medtronic plc is an Ireland-based healthcare technology company. The Company's technologies and therapies treat approximately 70 health conditions and include cardiac devices, surgical robotics, surgical tools, patient monitoring systems, and more. Its product category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral Maxillofacial & Dental; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging and Urological. Its services and solutions include Ambulatory Surgery Center Resources, Digital Connectivity Information Technology (IT) Support, Equipment Services & Support, Financial Services, Innovation Lab and Office-Based Sinus Surgery. Its medical specialties include Cardiac Surgery, Electrophysiology, Gastroenterology, Hernia Repair, Interventional Cardiology and Spine Surgery. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Medtronic PLC appears to be a good buy at the current price of $88.48, especially given its strong fundamentals and positive catalysts. The company raised its dividend for the 49th consecutive year, indicating a commitment to shareholder returns, and analysts project a revenue growth of 7.25%-7.75% for fiscal 2027. However, the stock has faced challenges, reflected in a 7.88% year-to-date decline. The forward P/E ratio is attractive at 14.93, suggesting potential for upside.

23 analysts cover MDT: 11 rate it Buy, 12 Hold and 0 Sell. The average price target is 111.76.